IQVIA (NYSE:IQV – Get Free Report) had its price objective lowered by investment analysts at Truist Financial from $286.00 to $265.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Truist Financial’s price objective points to a potential upside of 26.20% from the stock’s current price.
A number of other equities analysts have also issued reports on IQV. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Friday. Morgan Stanley cut their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday. Finally, The Goldman Sachs Group cut their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $261.56.
View Our Latest Report on IQVIA
IQVIA Stock Performance
Insiders Place Their Bets
In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. First Foundation Advisors boosted its position in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares during the last quarter. Team Hewins LLC lifted its position in IQVIA by 5.0% in the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after buying an additional 46 shares during the last quarter. Invera Wealth Advisors LLC lifted its position in IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after buying an additional 46 shares during the last quarter. Covestor Ltd lifted its position in IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after buying an additional 48 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
IQVIA Company Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
- Five stocks we like better than IQVIA
- 3 Monster Growth Stocks to Buy Now
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Investors Need to Know About Upcoming IPOs
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Stocks That Are Potential Takeover Targets in 2025
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.